Regulating the regulator: a survey of mechanisms from transcription to translation controlling expression of mammalian cell cycle kinase Aurora A
- PMID: 36067794
- PMCID: PMC9448500
- DOI: 10.1098/rsob.220134
Regulating the regulator: a survey of mechanisms from transcription to translation controlling expression of mammalian cell cycle kinase Aurora A
Abstract
Aurora Kinase A (AURKA) is a positive regulator of mitosis with a strict cell cycle-dependent expression pattern. Recently, novel oncogenic roles of AURKA have been uncovered that are independent of the kinase activity and act within multiple signalling pathways, including cell proliferation, survival and cancer stem cell phenotypes. For this, cellular abundance of AURKA protein is per se crucial and must be tightly fine-tuned. Indeed, AURKA is found overexpressed in different cancers, typically as a result of gene amplification or enhanced transcription. It has however become clear that impaired processing, decay and translation of AURKA mRNA can also offer the basis for altered AURKA levels. Accordingly, the involvement of gene expression mechanisms controlling AURKA expression in human diseases is increasingly recognized and calls for much more research. Here, we explore and create an integrated view of the molecular processes regulating AURKA expression at the level of transcription, post-transcription and translation, intercalating discussion on how impaired regulation underlies disease. Given that targeting AURKA levels might affect more functions compared to inhibiting the kinase activity, deeper understanding of its gene expression may aid the design of alternative and therapeutically more successful ways of suppressing the AURKA oncogene.
Keywords: Aurora Kinase A; cell cycle; mRNA processing; oncogene; transcription; translation.
Conflict of interest statement
We declare we have no competing interests.
Figures
Similar articles
-
Post-transcriptional control drives Aurora kinase A expression in human cancers.PLoS One. 2024 Nov 11;19(11):e0310625. doi: 10.1371/journal.pone.0310625. eCollection 2024. PLoS One. 2024. PMID: 39527514 Free PMC article.
-
Differential translation of mRNA isoforms underlies oncogenic activation of cell cycle kinase Aurora A.Elife. 2023 Jun 29;12:RP87253. doi: 10.7554/eLife.87253. Elife. 2023. PMID: 37384380 Free PMC article.
-
Elevated expression of Aurora-A/AURKA in breast cancer associates with younger age and aggressive features.Breast Cancer Res. 2024 Aug 28;26(1):126. doi: 10.1186/s13058-024-01882-x. Breast Cancer Res. 2024. PMID: 39198859 Free PMC article.
-
Structural basis for the design of allosteric inhibitors of the Aurora kinase A enzyme in the cancer chemotherapy.Biochim Biophys Acta Gen Subj. 2020 Jan;1864(1):129448. doi: 10.1016/j.bbagen.2019.129448. Epub 2019 Oct 30. Biochim Biophys Acta Gen Subj. 2020. PMID: 31676293 Review.
-
Insights into the non-mitotic functions of Aurora kinase A: more than just cell division.Cell Mol Life Sci. 2020 Mar;77(6):1031-1047. doi: 10.1007/s00018-019-03310-2. Epub 2019 Sep 27. Cell Mol Life Sci. 2020. PMID: 31562563 Free PMC article. Review.
Cited by
-
Post-transcriptional control drives Aurora kinase A expression in human cancers.PLoS One. 2024 Nov 11;19(11):e0310625. doi: 10.1371/journal.pone.0310625. eCollection 2024. PLoS One. 2024. PMID: 39527514 Free PMC article.
-
Emerging Role of Deuterium/Protium Disbalance in Cell Cycle and Apoptosis.Int J Mol Sci. 2023 Feb 4;24(4):3107. doi: 10.3390/ijms24043107. Int J Mol Sci. 2023. PMID: 36834518 Free PMC article. Review.
-
The role of Aurora kinase A in hepatocellular carcinoma: Unveiling the intriguing functions of a key but still underexplored factor in liver cancer.Cell Prolif. 2024 Aug;57(8):e13641. doi: 10.1111/cpr.13641. Epub 2024 Apr 8. Cell Prolif. 2024. PMID: 38590119 Free PMC article. Review.
-
Differential translation of mRNA isoforms underlies oncogenic activation of cell cycle kinase Aurora A.Elife. 2023 Jun 29;12:RP87253. doi: 10.7554/eLife.87253. Elife. 2023. PMID: 37384380 Free PMC article.
-
Preclinical Evaluation of JAB-2485, a Potent AURKA Inhibitor with High Selectivity and Favorable Pharmacokinetic Properties.ACS Omega. 2024 May 3;9(19):21416-21425. doi: 10.1021/acsomega.4c01752. eCollection 2024 May 14. ACS Omega. 2024. PMID: 38764682 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous